Alzheimer's Drug Approved by Health Canada
Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease.
Lecanemab aims to slow the early stages of the disease by targeting plaques in the brain. It is a lab-made antibody given by intravenous infusion, targeting the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer's treatment approved for use in the country.
Author's summary: Lecanemab approved to slow early Alzheimer's.
More News
- Can the United States Immediately Return to Nuclear Testing?
- 2025 NBA Cup TRACKER: Scores, Schedule, Standings
- Tomago’s slow death exposes folly of ‘Made in Australia’ dream
- An Illinois wealth tax would be a legal disaster
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- Billie Eilish Calls on Billionaires to Do More for People in Need
- Flat blaze in Island town extinguished by firefighters
- Employee consultation begins at Rio Tinto-led aluminium smelter over future operations
- Will vigilante justice emerge amid alleged calls for violence, analyst questions
- The easy way to check you’re being paid the right amount of super